Morning Market Movers: REPL, BIOA, DFNS, AXTI See Big Swings

RTTNews reports notable premarket moves ahead of Friday’s open, highlighting gainers including REPL (+131% to $12.49), AXT (+34% to $62.94), COHU (+24% to $57.70) and NWL (+19% to $6.11). Losers include BIOA (-53% to $11.64), DFNS (-49% to $43.50), GLUE (-29% to $16.00) and PN (-27% to $17.20).

Original reporting
Published Jul 31, 2026, 1:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 2:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefMarket movers
Primary signal
$REPL
Bullish
low confidence
Mentioned
$REPL · $AXTI · $BIOA · $DFNS
Relevance
4/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$REPLBullishLow
01

Why it matters

It provides only premarket price changes for multiple tickers, with no explanation of why the moves occurred. The main trading implication is short-term volatility and momentum versus mean reversion risk into the open.

02

Market read

This is primarily a volatility watchlist for the open, not a catalyst-driven news report.

03

What to watch

Premarket percentage moves can be distorted by low volume, wide spreads, and order imbalances; traders should verify regular-session liquidity and any halt/news context before sizing.

Relevance 4/10Novelty 2/10Timing: premarket before the opening bell

Background

The article is a premarket market wrap listing stocks with large percentage gains and losses ahead of the US open.

Company-level read

Ticker impact

$REPLBullishLow confidence
Context

Premarket shows Replimune Group up 131% at $12.49, signaling a high-volatility momentum setup into the open.

Expected impact

Likely continued elevated volatility near the open, but direction is uncertain without a catalyst.

Evidence & confidence

The text reports percentage change and price only, with no news driver or follow-through details.

$AXTIBullishLow confidence
Context

AXT, Inc. is up 34% in premarket to $62.94, indicating a potential breakout or squeeze risk before regular trading.

Expected impact

Short-term upside bias possible, with high risk of pullback if liquidity thins or sellers emerge.

Evidence & confidence

Only premarket pricing is disclosed; no fundamental or event information is provided.

$BIOABearishLow confidence
Context

BioAge Labs is down 53% premarket to $11.64, implying sharp downside momentum and elevated risk of further selling.

Expected impact

Near-term downside pressure is plausible, but magnitude could be exaggerated by thin premarket liquidity.

Evidence & confidence

The article reports the decline without any accompanying news, guidance, or filing.

$DFNSBearishLow confidence
Context

T3 Defense is down 49% premarket to $43.50, a large drawdown that can trigger volatility and stop-driven flows.

Expected impact

Could remain weak at the open, but a snapback is possible if selling is overdone.

Evidence & confidence

No event driver is included; only the premarket percentage move is stated.

Market effects

No sector-level conclusions are supported because the article is a multi-name premarket movers list with no shared catalyst.

None stated; the piece is US premarket focused.

Low; it does not connect moves to macro or global events.

Counterpoint

Without a disclosed catalyst, the biggest premarket movers may be driven by liquidity and positioning, making mean reversion more likely than trend continuation.

Key entities

  • Replimune Group, Inc.

    Reported up 131% premarket to $12.49.

  • AXT, Inc.

    Reported up 34% premarket to $62.94.

  • BioAge Labs, Inc.

    Reported down 53% premarket to $11.64.

  • T3 Defense Inc.

    Reported down 49% premarket to $43.50.

Related articles

$REPLMed

This Week at FDA: Inspection reorg, acting CBER chief eyes IND reforms, and more

FDA updates cover inspection reorganization plans, proposed IND reforms for early-stage biologics research, and accelerated approval of Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg) with Bristol Myers Squibb’s Opdivo for melanoma after PD-1 regimens. Other items include FDA workshops, Seegene EUA for an assay, and multiple drug/device recalls.

$REPLMedAI 8/10

FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial - The Cancer Letter

The FDA granted accelerated approval to Replimune’s RP1 (vusolimogene oderparepvec) for advanced melanoma in patients whose disease progressed after prior anti-PD-1 therapy, in combination with nivolumab, after a 10:3 advisory committee vote, according to The Cancer Letter.

$AXTIMedAI 8/10

AXTI Stock Soars As AI Demand Turns Earnings Corner

AXT Inc (NASDAQ: AXTI) shares rose about 18.6% after the company announced semiconductor capacity expansion tied to AI demand. The article cites Q2 revenue of $47.6M (vs $18.0M a year earlier) and adjusted EPS of $0.19. It also reports Q3 guidance EPS $0.30–$0.32 and revenue about $66M, plus analyst target updates.

$REPLMedAI 9/10

Replimune Wins FDA Accelerated Nod For TUDRIQEV In Advanced Melanoma

Replimune Group (REPL) said the FDA granted accelerated approval for TUDRIQEV plus Bristol Myers Squibb’s nivolumab for adults with unresectable advanced cutaneous melanoma after anti-PD-1 therapy. Based on the IGNYTE trial of 140 patients, the efficacy group reported a 24.2% objective response rate and 14.1-month median duration of response, with mostly mild-to-moderate adverse events.

$REPLHighAI 10/10

Third Time's the Charm: FDA Approves Replimune's Tudriqev (RP1) for Advanced Melanoma

On Aug 6, 2026, the FDA granted accelerated approval to Replimune’s Tudriqev (RP1) with nivolumab for adults with unresectable advanced cutaneous melanoma after progression on anti-PD-1 therapy. Based on IGNYTE (n=140), FDA efficacy-evaluable ORR was 24.2% with median DoR 14.1 months. Replimune set a $450,000 list price per course; approval is conditional on Phase 3 IGNYTE-3.

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.